CTA-PB

Business Context and Reporting Period

Company: E. I. du Pont de Nemours and Company (DuPont)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2000
Business Overview: DuPont operates globally in approximately 70 countries, deriving roughly 50% of revenues from outside the U.S. Key segments include Agriculture & Nutrition, Nylon, Performance Coatings & Polymers, Pharmaceuticals, Pigments & Chemicals, Pioneer, Polyester, Specialty Fibers, and Specialty Polymers.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2000 sales increased 13% year-over-year. Segment sales grew 12%, driven by 6% volume growth, 6% from the Pioneer acquisition, and 2% price increases, partially offset by a 2% negative currency impact.
• Earnings Decline: Reported Net Income decreased 25% in Q2 2000 compared to Q2 1999. This decline is primarily due to one-time charges totaling $418 million (pretax) in Q2 2000 versus $62 million in Q2 1999.
• Adjusted Performance: Excluding one-time items, earnings from continuing operations were $0.90 per share in Q2 2000, a 15% increase over the $0.78 per share in Q2 1999.
• Segment Highlights:
  • Pioneer: Earnings increased $85 million due to 100% ownership in 2000 versus 20% in 1999.
  • Performance Coatings: Earnings up 19% despite restructuring charges.
  • Nylon: Earnings down 15% due to higher raw material costs.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2000 Target: Management reaffirms the target of 17-20% earnings per share growth for the full year 2000.
• Second Half Expectations:
  • Raw material costs expected to remain high, with an estimated negative EPS impact of $0.20-$0.25 compared to H2 1999.
  • Volume growth expected to be slightly below the 6% rate achieved in the first half.
  • More than half of strategic business units expected to have higher U.S. dollar selling prices than H2 1999.
• Capital Allocation: Capital spending targeted at approximately $2.0 billion for the year. A share repurchase program was expanded to $2.5 billion, with intent to fund via monetization of non-strategic assets.

Risks and Contingencies

• Benlate Litigation: Significant pending litigation regarding "Benlate" 50 DF fungicide. Recent jury awards in Texas totaled approximately $23 million and $35 million (after statutory reductions). Management increased reserves by $100 million in Q2 2000. While liabilities could be significant to the Crop Protection segment, management does not anticipate a material adverse effect on consolidated financial position.
• Raw Material Costs: Earnings growth is sensitive to increases in petroleum-based feedstocks, natural gas, and paraxylene.
• Foreign Exchange: A stronger U.S. dollar negatively impacts worldwide sales and results.
• Healtheon/WebMD Warrants: An unrealized loss of $145 million is recorded in Other Comprehensive Income. A future charge to earnings may occur if the decline is deemed other than temporary.

Investor Verification Checklist

• One-Time Charges: Verify the impact of the $418 million in Q2 2000 one-time charges (Benlate accrual, Pioneer purchase accounting, restructuring) on reported earnings versus core operational performance.
• Benlate Reserve Adequacy: Monitor updates on the "Benlate" litigation reserve, given recent jury awards and the company's plan to appeal.
• Raw Material Hedging: Assess the company's ability to pass on higher raw material costs to customers in the second half of the year.
• Pioneer Integration: Confirm the realization of synergies and the impact of full consolidation of Pioneer on future cash flows.
• Share Repurchase Execution: Track progress on the expanded $2.5 billion share buyback program and its funding sources.